When we started Project Lightspeed the grand mission was to make a #vaccine for the world. Today, we announced at the #G20 Summit, together with our partner Pfizer, that we'll deliver 2 billion doses of our #COVID19 vaccine to low- and middle-income countries over the next 1.5 years. The first 1 billion doses will be provided this year.
This is one milestone in a string of many:
- As of yesterday, we've delivered ~540 million doses to >90 countries
- In parallel, we've increased our capacity for 2021 to up to 3 billion doses
- We reached agreements to deliver additional doses with many countries, incl. the EU, and most recently Turkey, which will receive 120 million #BNT162b2 doses
- We're continuing to conduct clinical trials to make our COVID-19 vaccine available to all who could potentially benefit. We've submitted data on BNT162b2’s tolerability and efficacy in 12- to 15-year-old adolescents; the #FDA has granted approval and we'e awaiting feedback from the European Medicines Agency
What motivates us is the steady decline in new COVID-19 cases as vaccination campaigns progress in many countries. Bringing the pandemic to an end is an immense challenge that we can only overcome together. We'll continue to work every day to contribute our part to achieving this goal.
To view or add a comment, sign in
To view or add a comment, sign in
One year after the World Health Organization declared #COVID19 a pandemic, we have several approved vaccines against the disease. Each step, each vaccinated person is important on our way forward to return to our normal lives again. In my first article on LinkedIn, I am looking back at the past 12 months.
To view or add a comment, sign in
To view or add a comment, sign in
Back when I was a young physician treating cancer patients, I learned how devastating the disease is - too often I had to tell patients that no further treatment options were left for them. Cancer is still one of the greatest challenges we are facing. The recent pandemic has put an immense strain on cancer patients and their access to care as well as on health care workers. It is also threatening the progress being made to address the life-threatening disease.
We founded BioNTech to reduce the suffering of people - we remain committed to our goal. On today's #WorldCancerDay, I would like to reinforce my commitment to this effort by making a #IAmAndIWill statement as part of the UICC international cancer awareness campaign:
I am Uğur Şahin, CEO and Founder of BioNTech SE, and I will continue to dedicate my work, together with all my colleagues, to aspire to develop changing cancer therapies and reduce suffering. #teambiontech
![Conversation starter Guide]()
To view or add a comment, sign in
To view or add a comment, sign in
All 27 EU member states received their first batches of our #COVID19 vaccine.
I can't think of a festive season that was more special to us. We are incredibly happy that the vaccination will start in many countries now. Based on the EU’s approach all member states will have access to COVID-19 vaccines at the same time and proportionately to the size of their population. This morning, I received the picture below showing the first batches arriving at their destination – only a few hours later another one was shared showing the first individual being vaccinated in Germany: a 101-year-old senior citizen. See article by Deutsche Welle: http://bit.ly/34KMCYF
A big thank you goes out to my colleagues and our partners who continued to work over Christmas to make this happen. For us at BioNTech SE and Pfizer this is the real spirit of Christmas.
I'm also happy and grateful that we agreed to supply Turkey with upto 30 million doses of our COVID-19 vaccine in 2021. The supply will start with more than 500K doses at the beginning of 2021. See article by Anadolu: http://bit.ly/38xwNps
We continue to further execute on our strategy to support a worldwide supply of vaccines. Get safe through the holidays, everyone.
To view or add a comment, sign in
To view or add a comment, sign in
The European Commission announced that it will follow the recommendation of the European Medicines Agency to grant Conditional Marketing Authorization for our #mRNA vaccine in the #EU.
We will begin shipping the vaccine shortly. This is a testament to the courage and groundbreaking work of all those involved in the R&D and distribution of the vaccine.
This is the 1st time in medical history that a vaccine has been developed and backed by safety and efficacy data from a large-scale trial with more than 44K participants, and formally approved in less than a year. It has now been granted a CMA, emergency use or temporary authorization in >40 countries worldwide. To date, over 800,000 people around the world have received our #mRNA COVID-19 vaccine.
My deep gratitude goes to everyone at #TeamBioNTech, #TeamPfizer and our partners for going above and beyond to enable this historic innovation. I also thank my companions of the past 30 years, including Christoph Huber, our co-founder and member of the Supervisory Board; our investors Thomas and Andreas Strüngmann, who have believed in #BioNTech from day one; and our colleagues and partners Katalin Karikó, Drew Weissman & Thomas Madden, along with the many other scientists who contributed to advancing mRNA as a new drug class.
To view or add a comment, sign in
To view or add a comment, sign in
Today, Özlem and I had the honor of speaking with German Chancellor Angela Merkel, the Federal Minister of Health Jens Spahn and the Federal Minister of Education and Research Anja Karliczek. It was a great opportunity to discuss project Lightspeed and highlight the amazing work of the entire #TeamBioNTech.
We left the conversation feeling even more inspired. Prior to a decision on approval of our #COVID19 vaccine by the European Medicines Agency (EMA) next week we shared our goal to make the vaccine widely available to help contain this pandemic. It was a special moment for all of us when the first people were vaccinated in the U.K. for the first time outside of the trials last week. We're thrilled that more than 140.000 people have received our vaccine in the U.K. alone.
We also discussed the tremendous importance of long-term research funding, international partnerships and our collaboration with Pfizer, the power of perseverance, and our pioneering scientific spirit. This spirit is what drove us to research mRNA vaccines and other types of immunotherapies for the past two decades. Without the continued encouragement of those who believed in us and in novel technologies - and without our team of colleagues from more than 60 nations - there would be no #mRNA vaccine.
![Kanzlerin zu virtuellem Besuch bei Impfstoffhersteller Biontech]()
To view or add a comment, sign in
To view or add a comment, sign in
Thank you, Boston Medical Center (BMC), you made our day! #bnt162b2 #covid19 #vaccine #Pfizer
On December 14th, Boston Medical Center received its first shipment of the COVID-19 vaccine. And staff are "feeling good" about this important turning point in the pandemic... 💃🏼 🕺🏼
We are excited to have been the first Massachusetts hospital to receive the Pfizer vaccine and are ready to start vaccinating our health care workers this week. 🎉
Check out our Instagram stories for more information about the vaccine delivery: https://bit.ly/3qZgOsw
To view or add a comment, sign in
To view or add a comment, sign in
With another week starting we have more news to share. Singapore, Mexico and Lebanon have joined the growing list of countries with regulatory bodies that have authorized our #COVID19 #vaccine for emergency use. We expect responses from other authorities over the coming days and weeks, and we are preparing submissions for several additional countries around the world. Each approval and authorization will help us to support a global supply.
In addition, we also published new data about #BNT162b2 from our German Phase 1/2 trial on medRxiv https://lnkd.in/dSqD5zB . All 37 participants vaccinated with BNT162b2 showed newly generated spike protein-specific CD4+ T cell responses, and more than 90% of the participants demonstrated CD8+ T cell responses. The majority of T cell responses were strong, well comparable to or significantly higher than memory responses of the same individuals against common viruses, such as cytomegalovirus, Epstein Barr virus and the influenza virus.
And, the antibodies generated in trial subjects were able to neutralize pseudo-viruses representing 19 diverse SARS-CoV-2 variants, indicating potential for broad protection against viruses with reported mutations.
We will keep you posted on any upcoming news!
To view or add a comment, sign in
To view or add a comment, sign in
We are proud that our #mRNA #COVID19 vaccine is available for high-risk populations in more and more countries! The FDA just authorized BNT162b2 for emergency use. As Americans get vaccinated over the next weeks and months, we hope that lives will be saved and COVID-19 will slowly come under control in the U.S. BNT162b2 has also been authorized for emergency and interim use in the U.K., Canada, Bahrain, Israel, Saudi Arabia, and Qatar.
We've plenty of reasons for optimism. Our latest #NEJM paper shows that the cumulative incidence of symptomatic COVID-19 cases among placebo and vaccine recipients began to diverge by 12 days after the 1st dose – as shown below. These data indicate an early onset of a partially protective effect of immunization.
We're learning a lot from the data generated by our studies and those of our peers. This is innovation in action – we all are quickly gathering new knowledge and acting upon it to face the virus.
Today’s news is the result of a collaborative effort. I am very proud of my team at BioNTech SE, and I’d like to express my gratitude for our colleagues at Pfizer and all those who helped, especially our trial participants all around the world for their trust. We are honored to play a role in this historic process, which is just beginning.
To view or add a comment, sign in
To view or add a comment, sign in
